These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 35621011)

  • 1. Non-small cell lung cancer with
    Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
    Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
    Russell MC; Garelli AM; Reeves DJ
    Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
    David GM; Maria Del Pilar BC; Cristina MR
    J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.
    Seo D; Lim JH
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
    Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
    Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
    Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944068
    [No Abstract]   [Full Text] [Related]  

  • 7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Yang X; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
    Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
    Hernandez L; Young M
    J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
    [No Abstract]   [Full Text] [Related]  

  • 11. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
    Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
    Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
    Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
    Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
    Burnett H; Emich H; Carroll C; Stapleton N; Mahadevia P; Li T
    PLoS One; 2021; 16(3):e0247620. PubMed ID: 33684140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
    Bai Q; Wang J; Zhou X
    Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
    Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
    Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
    Zhang W; Dong X
    J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.